📊 PHIO Key Takeaways
Is Phio Pharmaceuticals Corp. (PHIO) a Good Investment?
Phio Pharmaceuticals exhibits exceptional balance sheet strength with $17M cash, zero debt, and pristine liquidity supporting a dramatic revenue surge (+2987.5% YoY), yet the company remains deeply unprofitable with $4.0M operating losses and negative cash flow. Improving profitability metrics (net income loss -21.7%, EPS +80.6% YoY) suggest successful early commercialization, but unclear path to profitability and ongoing cash burn present material fundamental risks.
Phio Pharmaceuticals Corp. Key Strengths (PHIO)
- Exceptional balance sheet: $17M cash, zero long-term debt, 14.43x current ratio provides 4+ years cash runway at current burn rate
- Dramatic revenue acceleration at +2987.5% YoY from early-stage commercialization phase
- Improving profitability trajectory: net income losses shrinking 21.7% YoY, diluted EPS improving 80.6% YoY
PHIO Stock Risks: Phio Pharmaceuticals Corp. Investment Risks
- Massive operating cash burn of $4M offsetting revenue growth; company not yet self-funding operations
- Extreme negative margins (-1803.9% operating, -1732.9% net) indicate fundamental unprofitability at current scale
- Pharmaceutical commercialization highly binary; minimal revenue base ($231K) creates significant execution risk for achieving scale
- Operating cash burn duration unclear; despite strong cash position, sustained losses without revenue acceleration threaten viability
Key Metrics to Watch
- Quarterly revenue growth rate and gross margins as products scale
- Operating cash burn trajectory and path to break-even operations
- Cash runway duration at current burn rate vs. revenue growth acceleration needed
Phio Pharmaceuticals Corp. (PHIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.43x current ratio provides a solid financial cushion.
PHIO Profit Margin, ROE & Profitability Analysis
PHIO vs Healthcare Sector: How Phio Pharmaceuticals Corp. Compares
How Phio Pharmaceuticals Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Phio Pharmaceuticals Corp. Stock Overvalued? PHIO Valuation Analysis 2026
Based on fundamental analysis, Phio Pharmaceuticals Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Phio Pharmaceuticals Corp. Balance Sheet: PHIO Debt, Cash & Liquidity
PHIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Phio Pharmaceuticals Corp.'s revenue has declined by 38% over the 5-year period, indicating business contraction. The most recent EPS of $-46.76 indicates the company is currently unprofitable.
PHIO Revenue Growth, EPS Growth & YoY Performance
PHIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | N/A | -$1.7M | N/A |
| Q2 2020 | N/A | -$1.7M | N/A |
| Q1 2020 | N/A | -$2.1M | N/A |
| Q3 2019 | N/A | -$1.5M | N/A |
| Q2 2019 | N/A | -$1.9M | N/A |
| Q1 2019 | $21.0K | -$2.1M | N/A |
| Q3 2018 | N/A | -$1.5M | N/A |
| Q2 2018 | N/A | -$1.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Phio Pharmaceuticals Corp. Dividends, Buybacks & Capital Allocation
PHIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Phio Pharmaceuticals Corp. (CIK: 0001533040)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHIO
What is the AI rating for PHIO?
Phio Pharmaceuticals Corp. (PHIO) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHIO's key strengths?
Claude: Exceptional balance sheet: $17M cash, zero long-term debt, 14.43x current ratio provides 4+ years cash runway at current burn rate. Dramatic revenue acceleration at +2987.5% YoY from early-stage commercialization phase.
What are the risks of investing in PHIO?
Claude: Massive operating cash burn of $4M offsetting revenue growth; company not yet self-funding operations. Extreme negative margins (-1803.9% operating, -1732.9% net) indicate fundamental unprofitability at current scale.
What is PHIO's revenue and growth?
Phio Pharmaceuticals Corp. reported revenue of $231.0K.
Does PHIO pay dividends?
Phio Pharmaceuticals Corp. does not currently pay dividends.
Where can I find PHIO SEC filings?
Official SEC filings for Phio Pharmaceuticals Corp. (CIK: 0001533040) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHIO's EPS?
Phio Pharmaceuticals Corp. has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PHIO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Phio Pharmaceuticals Corp. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PHIO stock overvalued or undervalued?
Valuation metrics for PHIO: ROE of -24.3% (sector avg: 15%), net margin of -1,732.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PHIO's AI grade for 2026?
Our dual AI analysis gives Phio Pharmaceuticals Corp. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHIO's free cash flow?
Phio Pharmaceuticals Corp.'s operating cash flow is $-4.0M, with capital expenditures of $0.0. FCF margin is -1,732.9%.
How does PHIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,732.9% (avg: 12%), ROE -24.3% (avg: 15%), current ratio 14.43 (avg: 2).